0000-00-00 |
|
|
|
External link to document |
2023-04-04 |
1 |
Complaint |
November 29, 2016 (the “’651 Patent”).
b. U.S. Patent No. 8,492,359, “Lipid Formulations for…infringement of the ’651 Patent.
COUNT 2: INFRINGEMENT OF U.S. PATENT NO. 8,492,359
80. … acid-based medicines: U.S.
Patent Nos. 9,504,651 (Exhibit A); 8,492,359 (Exhibit B); 11,141,378 (Exhibit… them.
Among those patents are the Asserted Patents:
a. U.S. Patent No. 9,504,651, “Lipid…’320 Patent under 35 U.S.C. § 271(a) by using the patented apparatus covered by the ’320
Patent to make |
External link to document |
2024-07-11 |
101 |
Redacted Document |
15, 2008 provisional
application: U.S. Patent Nos.: 8,058,069, 8,822,668, and 9,364,435.
Case 3:23-cv…success of Comirnaty®, asserting five patents (across two patent families that date back to 2002
and …Comirnaty® infringes those asserted
patents. The asserted patents, however, do not claim the specific …attempt by Plaintiffs to leverage the patents-in-suit (or patent
family members thereof) into an unearned… of
the same patents-in-suit, as well as three additional family members to the patents-in-suit.2 Each |
External link to document |
2024-07-11 |
102 |
Redacted Document |
a single excerpt of
a claim from U.S. Patent No. 8,492,359 asserted in this case, both excerpts referring…Plaintiffs emphasize each patent’s generic reference
to mRNA, and each patent claim’s recitation of “an…Alnylam) is
asserting its own patents that are unrelated to the patents in this case. Plaintiffs’ request…this case patents purporting to relate to the discovery of a new lipid ingredient.
The patents at issue…claim from just one
of the six patents asserted in Alnylam (U.S. Patent 11,382,979), comparing it to a |
External link to document |
2023-07-10 |
17 |
Answer to Complaint |
vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359,
8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011.
…Office issued the ’651
Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”).
Each patent claims…manufacturing them.
Among those patents are the Asserted Patents:
a. U.S. Patent No. 9,504,651, “Lipid |
External link to document |
2023-08-14 |
29 |
Answer to Counterclaim |
vaccine
may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668,
… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011.
ANSWER…the
Asserted Patents, and unenforceability of the ’378 Patent, ’320 Patent, and ’098 Patent. Plaintiffs…was issued the ’359 Patent, the ’668 Patent, and
the ’435 Patent. Those patents speak for themselves… “’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”).
Each patent claims |
External link to document |
2024-07-11 |
99 |
Redacted Document |
of U.S. Patent No. 8,492,359, one of the patents asserted
here. For example, the ’979 patent claims, …of U.S. Patent No. 11,382,979, among others. Ex. G at 8-9, 15-18. And the
claims of that patent overlap…documents that Pfizer or BioNTech produced in
another patent infringement case involving Pfizer’s COVID-19 vaccine…irrelevant because Alnylam “involves different patents.” Ex. B at 6. That is mistaken for multiple
independent… 35-65 mol
% of a cationic lipid,” and the ’359 patent claims “[a] nucleic acid-lipid particle comprising |
External link to document |